On Tuesday, Pfizer Inc. (NYSE:PFE) shared topline data from a mid-stage study for a weight loss drug and reported fourth quarter earnings that beat consensus estimates.

Weight Loss Data

Pfizer released data from the Phase 2b VESPER-3 study of monthly maintenance dosing of PF'3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes.

The U.S. drug giant added the ultra-long-acting, injectable GLP-1 receptor agonist via a massive $10 billion Metsera, Inc. deal.

The ongoing 64-week study demonstrated statistically significant weight reduction with up to 12.3% mean placebo-adjusted weight loss at week 28.

At week 28, 10% and 12.3% placebo-adjusted weight loss were achieved in Arms 1 and 3, respectively, which are the low and medium monthly maintenance dosing regimens planned for inclusion in Phase 3.

These data show robust and continuous weight loss after switching to monthly dosing, with no plateau observed at week 28.

PF'3944 also maintained a well-tolerated and favorable safety profile through week 28 that is consistent with the GLP-1 RA class.

Observed gastrointestinal treatment-emergent adverse events were predominantly mild or moderate, with no more than one instance of severe nausea or vomiting observed ...